Human epidermal growth factor receptor 2-positive (HER2+) breast cancer accounts for about 20%–25% of all breast cancer cases and nearly 50% of these HER2+ cases also express hormone receptors (HRs), including estrogen receptor (ER) and/or progesterone receptor (PR) (2). This evidence concerns the gene NR4A1 and breast carcinoma.